← All trials
NCT00543127
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2007
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 872
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Spanish Breast Cancer Research GroupLead sponsor
- Hospital Mutua de TerrassaOverall official - principal investigator
- Hospital Virgen de la SaludOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- Consorci Sanitari de TerrassaOverall official - principal investigator
- OsakidetzaOverall official - principal investigator
- Hospital de JerezOverall official - principal investigator
- Complejo Hospitalario Juan CanalejoOverall official - principal investigator
- Hospital Municipal de BadalonaOverall official - principal investigator
- Hospital de TorreviejaOverall official - principal investigator
- Hospital Madrid Norte SanchinarroOverall official - principal investigator
- Hospital Carlos HayaOverall official - principal investigator
- Hospital Virgen de la VictoriaOverall official - principal investigator
- Complejo Hospitalario de Especialidades Juan Ramón JimenezOverall official - principal investigator
- Hospital Comarcal de BarbastroOverall official - principal investigator
- Hospital Clinico Lozano BlesaOverall official - principal investigator
- Hospital General de GuadalajaraOverall official - principal investigator
- Hospital Virgen de los LiriosOverall official - principal investigator
- Hospital Universitario Puerta del MarOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- Universidad de MurciaOverall official - principal investigator
- University of SevilleOverall official - principal investigator
- Hospital Universitario Ntra. Sra. de La CandelariaOverall official - principal investigator
- Miguel Hernández UniversityOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of Las Palmas de Gran CanariaOverall official - principal investigator
- Centro Oncológico de GaliciaStudy chair
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.